Myeloma

The Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, also known as EPd, for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor.

Treating people with cancer requires the coordination of complex care, and adding a clinical trial to the mix can pose more challenges.

A recent study found that fatigue reported among newly diagnosed patients with multiple myeloma may predict survival outcomes.

Preliminary findings showed that Revlimid (lenalidomide) significantly prolonged progression-free survival compared with observation in patients with smoldering multiple myeloma.

The Food and Drug Administration has granted a priority review to a new drug application for selinexor (KPT-330) for the treatment of patients with penta-refractory multiple myeloma.

The Food and Drug Admnistration has approved a once-weekly dosing option of Kyprolis (carfilzomib) to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

September is Blood Cancer Awareness month and CURE’s latest issue is dedicated to these diseases. And we have a sneak peek at what’s inside:

A 16-member team, including five patients with multiple myeloma, hiked through Iceland to raise money for disease research in hopes of finding a cure.

Injectable forms of medication may benefit patients with blood cancers.

Previously, there were concerns that older patients would not be able to handle the toxicities of the procedure, or that their stem cells, which are older, would not work as well. But that proved to not be the case.

The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Empliciti (elotuzumab) for use in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following two or more prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor (PI).

See what CURE readers have to say about our previous issues.

A patient's bone health history may offer clues into their myeloma outcomes, according to a recent study.

Understanding these outcomes is important in planning treatments and mitigating the possibility of patients stopping their treatment.

Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.

Here is what one expert says about the right time to start treating relapsed multiple myeloma.

This hike marks the fifth continent to be visited by a Moving Mountains for Multiple Myeloma team

Five leading cancer organizations came together to establish four steps that patients of all malignancies can turn to as they navigate their experience.

MMRF Honored for Fifteenth Year for Outstanding Stewardship of Donors’ Funds

Dewayne Johnson is the first of hundreds of patients to take Monsanto to trial, claiming that Roundup caused them to get cancer. His case will be seen even sooner than others because in California dying plaintiffs can be given expedited trials.

The Food and Drug Administration (FDA) approved the supplemental New Drug Application to add to the U.S. Prescribing Information for Kyprolis (carfilzomib) for the treatment of patients with relapsed or refractory multiple myeloma.

Cancer affects many aspects of a person’s life, such as the overall quality of their day-to-day living, but what if a person didn’t have the full-blown disease already? Could a precursor or asymptomatic stage of the disease still burden them?

A two-drug regimen improved outcomes for patients with myeloma when given before a stem cell transplant.

Researchers are considering whether some smoldering myelomas warrant treatment and which regimens are best.

When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine the most effective treatment method, according to Jeffrey Wolf, M.D.

A lack of vitamin D can have major impacts on myeloma treatment outomes.

Four oncology nurses were recognized during the inaugural event for their efforts to prioritize the health of patients’ bone health during treatment.

It takes a lot to call something a revolution in medicine ... The most important, of course, is its impact on people’s lives — particularly, a cure for illness or a major extension of life. A revolution also implies a sweeping cataclysmic change, one that is disruptive and boldly states that things will no longer be the same.